A link between long-term natalizumab dosing in MS and PML

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 3, 2016, Pages

  Major, Eugene O ^a   Nath, Avindra ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; HUMAN; LONG TERM CARE; MULTIPLE SCLEROSIS; PATIENT RISK; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK FACTOR; TREATMENT OUTCOME;

EID: 85003857560     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000235     Document Type: Editorial

References (10)

1. Berger JR, Fox RJ. Reassessing the risk of natalizumabassociated PML. J Neurovirol Epub 2016 Feb 3.
2. Biogen Medical Information. Tysabri (Natalizumab): PML Incidence in Patients Receiving TYSABRI. Available at: http://medinfo.biogen.com. Accessed January 6, 2016.
3. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47.
4. Meira M, Sievers C, Hoffman F, et al. MiRNA 126: a novel route for natalizumab action? Mult Scler 2014; 10:1363-1370.
5. MeiraM, Sievers C, Hoffman F, et al. Natalizumab-induced POU2AF1/SpiB upregulation: a possible route for PMLdevelopment. Neurol Neuroimmunol Neuroinflamm 2016; 3:e223. doi: 10.1212/NXI.0000000000000223.
6. Marshall L, Ferenczy M, Daley F, et al. Lymphocyte gene expression and JC virus non-coding control region sequences are linked with risk of PML. J Virol 2014;88:5177-5183.
7. Zhovtis L, Frohman T, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neuropsychiatry Epub 2016 Feb 25.
8. Wortman MJ, Lundberg P, Dagdanova A, et al. Opportunistic DNA recombination with Epstein Barr virus at sites of control region rearrangements mediate JC virus neurovirulence. J Infect Dis 2016;213:1436-1443.
9. Frohman EM, Monaco C, Remington G, et al. JC virus in CD 341 and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014; 71:596-602.
10. Major EO. PML re-emerges in natalizumab treated MS patients: new cases; same concerns. N Engl J Med 2009; 361:1038-1040.